erdafitinib (Balversa)

Indications

• treatment of advanced bladder cancer with an FGFR3 or FGFR2 aberration failing platinum-based chemotherapy

Dosage

• starting dose of 8 mg once daily
• increase to 9 mg daily if serum phosphate < 5.5 mg/dL, between days 14 & 17.

Tabs: 3 mg, 4 mg, 5 mg

Monitor

• serum phosphate

Adverse effects

• central serous retinopathy or retinal pigment epithelial detachment resulting in visual field defect (25%)
• increased serum phosphate, increased serum creatinine
• increased serum ALT, increased serum alkaline phosphatase
• decreased serum sodium
• stomatitis, fatigue, diarrhea, dry mouth, onycholysis

Laboratory

• FDA-approved companion diagnostic therascreen FGFR RGQ RT-PCR Kit

Mechanism of action

• inhibits FGF receptor

More general terms

• small inhibitory antineoplastic agent (ib drug)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=67462786